Picture of Hyloris Pharmaceuticals SA logo

HYL Hyloris Pharmaceuticals SA Share Price

0.000.00%
be flag iconLast trade - 00:00
HealthcareAdventurousSmall CapNeutral

Momentum

Relative Strength (%)
1m-12.36%
3m-10.58%
6m-16.17%
1yr-25.79%
Volume Change (%)
10d/3m+56.28%
Price vs... (%)
52w High-21.28%
50d MA-11.31%
200d MA-7.86%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-39.92%
Return on Equity-33.58%
Operating Margin-576.97%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202431st Dec 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Hyloris Pharmaceuticals SA EPS forecast chart

Profile Summary

Hyloris Pharmaceuticals SA is a Belgium-based bio-pharmaceutical company. The Company focus is on re-engineering cardiovascular products with a wide range of therapeutic indications and dosage forms. It has two partnered commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, and Maxigesic IV, dual mode-of-action non-opioid analgesic for the treatment of post-operative pain. Additionally, it develops the strategy of reformulating and repurposing already-approved pharmaceuticals primarily utilize the 505(b)(2) regulatory pathway in the U.S. and similar pathways in other countries, which are specifically designed for pharmaceutical agents for the safety and efficacy. It also creates new and different solutions for the approved pharmaceuticals along with the technological requirements.

Directors

    Last Annual
    December 31st, 2023
    Last Interim
    December 31st, 2023
    Incorporated
    March 31st, 2017
    Public Since
    June 29th, 2020
    No. of Employees
    24
    Sector
    Pharmaceuticals
    Industry
    Healthcare
    Exchange
    be flag iconEuronext - Brussels
    Shares in Issue
    28,000,374
    Blurred out image of a map
    Address
    Boulevard Gustave Kleyer 17, LIEGE, 4000
    Web
    https://hyloris.com/
    Phone
    +32 43460207
    Auditors
    KPMG Reviseurs d Entreprises SCc.

    HYL Share Price Performance

    Upcoming Events for HYL

    Hyloris Pharmaceuticals SA Annual Shareholders Meeting

    Similar to HYL

    Picture of Biosenic SA logo

    Biosenic SA

    be flag iconEuronext - Brussels

    Picture of Fagron NV logo

    Fagron NV

    be flag iconEuronext - Brussels

    Picture of Mithra Pharmaceuticals SA logo

    Mithra Pharmaceuticals SA

    be flag iconEuronext - Brussels

    Picture of Financiere de Tubize SA logo

    Financiere de Tubize SA

    be flag iconEuronext - Brussels

    Picture of UCB SA logo

    UCB SA

    be flag iconEuronext - Brussels

    FAQ